FDA Drug Approval: Sociology, Psychology, Biology & Business
This paper applies an interdisciplinary framework to examine the Food and Drug Administration's drug approval process. Drawing on sociology, psychology, biology, and business, it analyzes how pharmaceutical industry relationships shape regulatory behavior, how psychological biases affect FDA reviewers, how selective clinical trial design can obscure drug side effects, and how profit-driven corporate strategies result in expedited — and sometimes harmful — drug approvals. An annotated bibliography supports the analysis with peer-reviewed sources addressing pharmaceutical lobbying, direct-to-consumer advertising, institutional corruption, and drug repurposing.
- Introduction: Interdisciplinary Approach to FDA Regulation: Defines interdisciplinarity and introduces FDA analysis
- Sociology of FDA Drug Approval: Industry ties shape regulatory culture and approvals
- Psychology of Regulatory Decision-Making: Personal biases influence FDA reviewers toward industry
- Biology and Drug Interaction in Clinical Trials: Selective trial populations obscure harmful side effects
- Business Interests and Pharmaceutical Influence: Profit motives drive incomplete drug safety disclosure
- Annotated Bibliography: Six sources on FDA and pharmaceutical regulation
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- The paper uses a clearly structured interdisciplinary framework, dedicating a focused section to each discipline (sociology, psychology, biology, business), which makes the argument easy to follow and demonstrates genuine cross-disciplinary thinking.
- Each disciplinary section is supported by specific academic citations, grounding the analysis in published research rather than unsupported opinion.
- The annotated bibliography adds value by briefly explaining the contribution and limitations of each source, reinforcing the paper's analytical depth.
Key academic technique demonstrated
The paper demonstrates disciplinary triangulation — using multiple academic lenses to examine a single complex problem. Rather than simply describing the FDA, the author applies each discipline to reveal a different layer of regulatory failure, from sociological conflicts of interest to biological gaps in clinical trial design. This technique shows how no single perspective fully explains the issue, justifying the interdisciplinary approach.
Structure breakdown
The paper opens with a definition of interdisciplinarity and a statement of purpose, then moves through four evenly weighted disciplinary sections. Each section is roughly one paragraph and introduces a distinct angle on the same central problem. The paper closes with an annotated bibliography of six sources, each summarized for its specific contribution to the argument. The structure is straightforward and well-suited to an undergraduate-level interdisciplinary assignment.
Introduction: Interdisciplinary Approach to FDA Regulation
Interdisciplinarity is defined as the combination of two or more academic disciplines to achieve a common task. Using an interdisciplinary approach, a person can make connections between concepts and ideas across different disciplinary boundaries. By drawing knowledge from several disciplines, one can address a problem effectively and thoroughly. There are cases where a single approach would not be suitable for a particular problem, and interdisciplinarity better equips researchers to tackle the problem at hand. Combining the perspectives of two or more disciplines allows a researcher to understand a complex subject more completely.
This is precisely the case when attempting to understand the multitude of ways the Food and Drug Administration (FDA) and its subsidiaries approve foods and medications with regard to big business, financial priorities, and political interests. This is a complex subject that can only be fully understood by combining aspects from different disciplines such as sociology, psychology, biology, and business. By combining insights from these disciplines, we can better appreciate the complexity involved in the regulatory process and understand how the FDA approves medications.
Sociology of FDA Drug Approval
The structure of the FDA comes into question when one examines the sociology of its drug approval process. It has been shown that most regulatory employees began their careers in the pharmaceutical industry (Abraham, 2008). This means they have established "friendly relations" with the industry, which has an effect on their drug approval decisions. Due to career development incentives, regulators will try to maintain these friendly relations with industry, as they may plan to return to industry positions — or industry professionals may move into regulatory roles. In such cases, the regulatory agency ends up prioritizing the interests of the industry over the interests of the consumer.
While the FDA was formed to serve the interests of the public, it has over time begun to serve the interests of pharmaceutical companies. This has resulted in the drug approval process being expedited and long-term drug effects being overlooked (Busfield, 2006). This phenomenon — sometimes called regulatory capture — represents a fundamental tension at the heart of pharmaceutical oversight.
Psychology of Regulatory Decision-Making
Employees of the FDA often have personal links to pharmaceutical companies, links formed when they began their careers in those companies before transitioning to regulatory work. For many of these regulators, former colleagues remain friends, and those personal relationships can influence decisions to approve drugs. It is human nature to favor a familiar party over an unfamiliar one. This dynamic plays out in practice, as FDA regulators tend to trust the data submitted regarding the effects of a drug (Mukherji, Janakiraman, Dutta, & Rajiv, 2017).
Considering that the FDA cannot independently review each drug submitted for approval, it will often rely on the data submitted by the applicant and approve drugs based on that data (Barber IV & Diestre, 2019). There are unconscious cognitive cues that a regulator may carry toward a company they previously worked for, resulting in a tendency to trust that company and advocate for the approval of its drug. Understanding these cognitive biases is essential to understanding how personal psychology shapes regulatory outcomes.
Always verify citation format against your institution’s current style guide requirements.